Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

ARRY 7.54 +0.14 (1.89%)
price chart
Why Array BioPharma Inc. Shares Skyrocketed 51% in January
What: Shares of Array BioPharma (NASDAQ: ARRY ) , a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ, after announcing a pipeline acquisition from ...
Strong On High Volume: Array BioPharma (ARRY)  TheStreet.com
Insights On Trending Biotech Stocks - Array Biopharma (NASDAQ:ARRY), CTI ...  Wall Street Observer
Why Array Biopharma Inc's Shares Skyrocketed
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Drug News Shoots Array BioPharma Inc. (ARRY) Higher, Bulls Swarm  Schaeffers Research (blog)
Array Announces Agreement To Acquire ENCORAFENIB (LGX818)  MarketWatch
Why Array Biopharma Inc. Stock Roared Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Why Array Biopharma (ARRY) Stock Surged Yesterday  Bidness ETC
Array BioPharma: When Losing a Partnership Is Good News  24/7 Wall St.
Related articles »  
Does This 50% Price Target Hike For Array BioPharma Inc. Make Sense?
What: Shares of Array BioPharma (NASDAQ: ARRY ) , a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from brokerage firm Stifel Nicolaus.
Array Biopharma Inc. (NASDAQ:ARRY) Is going to Buy Worldwide Rights  Inside Trade
Company News: Array Biopharma Inc (NASDAQ:ARRY)  Realist Investor
Array BioPharma Inc. Short Interest Disclosure
Array BioPharma Inc. (NASDAQ:ARRY) stated gains of 1,914,605 shares or 8.1% in the short interest. The short interest registered from 23,749,847 on February 13,2015 to 25,664,452 on February 27,2015.
Form 8-K ARRAY BIOPHARMA INC For: Mar 02
BOULDER, Colo., March 2, 2015 -- Following announcements from both Novartis and GlaxoSmithKline regarding close of their transactions, Array BioPharma Inc. (NASDAQ: ARRY) today announced the completion of both the binimetinib and encorafenib ...
Array BioPharma Inc. (NASDAQ:ARRY) Update: Array BioPharma appoints ...  Wall Street Pulse
Aggressive Stocks: Extreme Networks Inc. (NASDAQ:EXTR), Array BioPharma ...  eMarketsDaily
Update: Array BioPharma Inc. Short Interest Grows by 19.5%
Array BioPharma Inc. (NASDAQ:ARRY) reported a rise of 19.5% or 3,870,322 shares in its short interest. The short figure came in at 18.3% of the total floats.
Share Price of Array BioPharma Inc. Drops by -3.4%  Ashburn Daily
Closing Bell Reports: First Solar, Inc. (FSLR), Array BioPharma, Inc. (ARRY ...  WallStreet Scope
Array BioPharma Inc. Price Target Update
Array BioPharma Inc. (NASDAQ:ARRY): The stock price is expected to reach $ 11 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $15 while the lower estimate is at $9.
Analyst Rating Update on Array BioPharma Inc.
Array Biopharma Inc (NASDAQ:ARRY) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 1 by 7 Wall Street Analysts.
Array BioPharma execs awarded $1.4M in stock for Novartis deal  BizWest Media
Director of Array BioPharma Inc Discloses Insider Trading  Ashburn Daily
Worth Watching Healthcare Sector Stocks - Array Biopharma Inc (ARRY ...
Array Biopharma Inc (NASDAQ:ARRY) increased 1.24% and closed at $7.33 in the last trading session with the overall traded volume of 2.75 million shares, versus the average volume of 2.56 million shares.